Claudia D’Augusta

Chief Financial Officer at VectivBio

Dr. Claudia D’Augusta has over 20 years of experience in the field of corporate finance, capital markets and M&A.

She was most recently Chief Financial Officer of Therachon prior to its acquisition by Pfizer in early July 2019. Previously she served as General Manager at TiGenix after its acquisition by Takeda. Prior to this appointment, Claudia was Chief Financial Officer of TiGenix, where she led the company’s IPO on Nasdaq in 2016, served as a member of the Executive Committee and held responsibility for the Finance, Legal and Investor Relations areas. She also served as the Chief Financial Officer of Cellerix and led its merger with TiGenix, a company listed on Euronext. Before joining Cellerix in 2004, Claudia was Finance Director of Aquanima (Santander Group). Previous experiences include Deloitte & Touche in Milan and Apax Partners in Madrid.

Dr. Augusta holds a bachelor’s degree in Economics and a Ph.D. in Business Administration from Bocconi University, Italy.


Org chart


Teams


Offices

This person is not in any offices


VectivBio

VectivBio AG is a global biotechnology company committed to making a difference in the lives of patients suffering from serious rare diseases.


Industries

Headquarters

Basel, Switzerland

Employees

11-50

Links